Recurrent Founder Variant in Inherited FVII Deficiency: Molecular Spectrum Analysis in Southeast China Recurrent Founder Variant in Inherited FVII Deficiency: Molecular Spectrum Analysis in Southeast China

Recurrent Founder Variant in Inherited FVII Deficiency: Molecular Spectrum Analysis in Southeast China Recurrent Founder Variant in Inherited FVII Deficiency: Molecular Spectrum Analysis in Southeast China | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Recurrent Founder Variant in Inherited FVII Deficiency: Molecular Spectrum Analysis in Southeast China Recurrent Founder Variant in Inherited FVII Deficiency: Molecular Spectrum Analysis in Southeast China Longying Ye, Langyi Qin, Saifang Wang, Yanhui Jin, Lihong Yang, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4674402/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background Factor VII (FVII) deficiency is a rare congenital coagulation disorder inherited in an autosomal recessive manner, characterized by reduced plasma FVII levels. Several variants in the F7 gene have been identified across different populations, with higher prevalence in certain regions. However, limited reports exist on predominant variants in Chinese and East Asian populations, highlighting the need for this study to fill the gap and improve understanding of genotype-phenotype correlations. Result This study characterizes severe FVII deficiency in 85 unrelated Chinese families, 57 exhibited severe FVII defects. Notably, 31 out of 57 experienced various bleeding manifestations, with the most prevalent being gingival bleeding, epistaxis, and menorrhagia. The Pearson's rank correlation test yielded correlation coefficients of − .496 (P = .000), − .266 (P = .014), and .149 (P = .175) between FVII activity and PT, FVII activity and bleeding scores, and PT and bleeding scores, respectively. Direct sequencing of the exons of the F7 gene and its border regions was conducted on all patients. The five variants with the highest allele frequencies were p.Arg364Gln, p.His408Gln, p.Arg337Cys, p.Cys10Profs16, and p.Cys389Gly. The p.Arg364Gln variant was identified in 11 individuals with homozygotes and 6 with compound heterozygosity, with the highest allele frequency of 30.51%. The variants p.Gln160Leu, p.Leu170*, p.Ser329Pro, and p.Trp344Gly were previously identified and reported by our research group. Additionally, a novel variant, p.Ile421Serfs76, is reported for the first time. This study, representing one of the largest cohorts of FVII variants in China, suggests that the prevalence of FVII deficiency may be underestimated. This conclusion is supported by the high proportion of asymptomatic subjects found to have low FVII levels. Conclusion The findings of this study, which represents one of the largest cohorts of FVII variants in China, indicate that the prevalence of FVII deficiencies may be underestimated. This is due to the high proportion of asymptomatic individuals with low FVII:C levels. The significant association between FVII:C levels, prothrombin time, and bleeding symptoms highlights the necessity for continued genetic analysis to enhance our comprehension of genotype-phenotype correlations and to refine diagnostic and management strategies for FVII deficiency in the Chinese population. Factor VII Deficiency Inherited bleeding disorders Variant Gene frequence Figures Figure 1 Figure 2 Figure 3 1 INTRODUCTION Factor VII (FVII) (OMIM: 227500) is a key factor in the initiation of coagulation. FVII deficiency initially reported by B. Alexander et al. in 1951[ 1 ], is a rare congenital bleeding disorder characterized by low or undetectable plasma levels of FVII, affecting approximately 1 in 500,000 people worldwide[ 2 ]. It is caused by variants in the F7 gene located in the 13q34 region of the human chromosome. Patients with the disease exhibit reduced FVII activity (FVII:C) in plasma, with clinical bleeding symptoms varying greatly from asymptomatic to severe[ 3 ]. The severity of clinical manifestations is closely linked to the number, location, and functional impact of the gene variants[ 4 ]. However, there is a close connection between the number of gene variants, their locus, and their impact on function[ 5 , 6 ]. Variants leading to the complete absence of active plasma FVII are linked to severe phenotypes, such as neonatal death or irreversible organ damage, including intracranial hemorrhage (ICH)[ 7 ]. However, even trace amounts of active protein, adequate to initiate coagulation, markedly influence the phenotype[ 8 ]. This is particularly true when genetic information is combined with relevant clinical data and modeling analyses, aiding in determining the pathogenicity of a variant[ 9 – 11 ]. The FVII Variant Database ( https://www.hgmd.cf.ac.uk/docs/login.html ) has cataloged over 200 variants in the F7 gene, primarily identified through small patient studies and individual case reports. This extensive database provides valuable insights into the genetic diversity and pathogenic mechanisms underlying FVII deficiency. In this study, additional genetic profiles can enhance our understanding of genotype-phenotype correlations in this rare coagulation disorder. We conducted a comprehensive analysis of variants and clinical presentations in 85 probands diagnosed with FVII deficiency, along with their respective relatives from the Chinese population. The data were collected over a fourteen-year period from 2010 to the present at the First Affiliated Hospital of Wenzhou Medical University. Genetic counseling was offered to other relatives upon identification of one or more variants in a family. The objective of this study was to investigate the correlation between genotype and phenotype and to summarize the specific variant spectrum of the F7 gene in 85 patients with FVII deficiency from the Chinese population. 2 MATERIALS AND METHODS 2.1 Participants The retrospective cohort study was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. A total of 85 unrelated probands (FVII:C < 72% ) from 2010 to 2024 in our study provides a reasonable sample size to investigate FVII deficiency. The parents of probands numbered 1, 3, 6, 7, 8, 12–15, 24, and 25 are consanguineous (Table 1 ). The patient's demographic details, including age, sex, bleeding history, and consanguinity, were duly recorded. Exclusion criteria included a history of hepatic and renal disease, as well as acquired FVII defects. Among the population with detected variants, 66.1% exhibited symptoms indicative of bleeding, while 33.9% did not demonstrate any such symptoms. Other platelet or coagulation factor defects were also excluded. Bleeding scores of 85 patients were calculated according to ISTH-BAT, a bleeding assessment tool that Rodeghiero introduced[ 12 ]. The normal ranges for bleeding scores are 0–3 for adult males and 0–5 for adult females. The FⅦ levels were measured before transfusion. Other platelet or coagulation defects were excluded. Details of patients with detected variants are presented in Table 1 , whilst information of patients without detected variants is provided in Supplementary Table 1. The reference sequences table is included in Supplementary Table 2 (both supplementary tables are available as separate files) Table 1 Laboratory Findings and Clinical Phenotypes of Patients with Mutated FVII Deficiency. Note : The meaning of all abbreviations has been previously indicated. Sr.no Gender/Age PT(s) FⅦ:C(%) Bleeding manifestation Bleeding score Nucleotide change Mature protein alteration Predicted pathogenicity Consanguinity carriers/families Zygosity 1 F/23 30.9 3 SB 4 c.1224T > G His408Gln Damaging Yes 3/6 Homo 2 M/7 32.8 3 PB/EP/SB 3 c.27_28delCT Cys10Profs*16 Damaging No 2/5 Homo 3 M/41 35.1 3 N 0 c.1090C > T Arg364Trp Damaging Yes 2/4 Homo 4 F/72 26.5 2 N 0 c.27_28delCT Cys10Profs*16 Damaging No N Homo 5 M/53 34 2 GB/PB 3 c.1090C > T Arg364Trp Damaging No N Homo 6 M/38 37.8 2 EB/EP/HU 7 c.1030T > G Trp344Gly Damaging Yes 5/7 Homo 7 F/27 31.1 2 EP/MN 4 c.1090C > T Arg364Trp Damaging Yes N Homo 8 F/55 36.2 3 GB/SB 3 c.1091G > A Arg364Gln Tolerable Yes N Homo 9 F/23 20.3 3 N 0 c.1009C > T Arg337Cys Damaging No 3/4 Homo 10 F/70 38.7 3 N 0 c.1091G > A Arg364Gln Tolerable No N Homo 11 F/67 30.8 3 N 0 c.1091G > A Arg364Gln Tolerable No N Homo 12 M/36 32.5 3 N 0 c.1091G > A Arg364Gln Tolerable Yes N Homo 13 F/25 42.1 3 GB/PB 3 c.1091G > A Arg364Gln Tolerable Yes N Homo 14 M/48 30.9 4 EP 1 c.1224T > G His408Gln Damaging Yes 3/5 Homo 15 M/57 33.8 4 N 0 c.1091G > A Arg364Gln Tolerable Yes N Homo 16 F/48 39.3 2 N 0 c.1165T > G Cys389Gly Damaging No 3/6 Homo 17 M/56 30.2 3 ICB 7 c.722C > A Thr241Asn Damaging No 3/4 Homo 18 F/75 39.1 2 N 0 c.1224T > G His408Gln Damaging No N Homo 19 M/75 36.8 2 N 0 c.1165T > A Cys389Gly Damaging No N Homo 20 F/53 53.8 4 N 0 c.1009C > T Arg337Cys Damaging No N Homo 21 F/54 34.2 6 N 0 c.1091G > A Arg364Gln Tolerable No 3/5 Homo 22 M/75 27.2 3 N 0 c.27_28delCT Cys10Profs*16 Damaging No N Homo 23 M/35 36.1 2 N 0 c.1091G > A Arg364Gln Tolerable No N Homo 24 M/32 26.7 6 N 0 c.910G > A Ala304Thr Damaging Yes 2/4 Homo 25 F/31 20.5 8 GB 2 c.1009C > T Arg337Cys Damaging Yes N Homo 26 m/28 28.3 3 MN 1 c.1009C > T Arg337Cys Damaging No N Homo 27 m/54 32.2 3 GI-MA 3 c.1091G > A Arg364Gln Tolerable No N Homo 28 F/56 37.9 2 GB 4 / c.1165T > G IVS6 + 1G > T Cys389Gly / Damaging No N Compound het 29 F/47 25.3 4 N 0 N IVS1a + 5G > A IVS6 + 1G > T / / No N Compound het 30 F/57 31.2 2 GB 1 c.1165T > G c.1224T > G Cys389Gly His408Gln Damaging Damaging No 3/5 Compound het 31 M/67 24.5 8 ICB 4 c.27_28delCT c.1238G > C Cys10Profs*16 Arg413Pro Damaging Damaging No 4/6 Compound het 32 F/52 19.9 15 N 0 c.752C > T c.1165T > G Ala251Val Cys389Gly Damaging Damaging No 5/7 Compound het 33 M/59 32.8 3 EP 1 c.1165T > G c.1224T > G Cys389Gly His408Gln Damaging Damaging No N Compound het 34 F/40 22.7 4 N 0 c.1009C > T c.1224T > G Arg337Cys His408Gln Damaging Damaging No N Compound het 35 F/43 27.1 4 N 0 c.1009C > T c.27_28delCT Arg337Cys Cys10Profs*16 Damaging Damaging No 2/4 Compound het 36 M/55 39.6 2 N 0 c.27_28delCT c.1091G > A Cys10Profs*16 Arg364Gln Damaging Tolerable No 4/6 Compound het 37 F/52 19.4 16 MN 1 c.691-693delTTG c.1224T > G Leu170* His408Gln Damaging Damaging No 3/4 Compound het 38 F/21 36.3 2 EP/GB/PPH 7 c.1201A > G / Lys401Glu IVS5-1G > A Tolerable / No N Compound het 39 F/43 35.4 2 MN 1 c.1224T > G c.1238G > A His408Gln Arg413Gln Damaging Damaging No N Compound het 40 F/66 21.8 13 GI-MA 1 c.1238G > A / Arg413Gln IVS6 + 1 G > T Damaging / No N Compound het 41 F/34 33.1 2 N 0 c.1091G > A c.1238G > A Arg364Gln Arg413Gln Tolerable No 3/5 Compound het 42 F/47 36.1 2 MN 1 / c.1238G > A IVS6 + 1G > T Arg413Gln / Damaging No N Compound het 43 F/30 35.7 2 SB/GB/PB 5 c.1091G > A c.1224T > G Arg364Gln His408Gln Tolerable No N Compound het 44 F/61 38.8 3 SDH 6 c.1224T > G / His408Gln IVS5 + 1G > A Damaging / No N Compound het 45 F/60 34.8 3 GI-MA/GB/EP 5 c.1224T > G c.698-162insT His408Gln / Damaging / No 3/6 Compound het 46 M/25 25.2 3 PPH 3 c.1009C > T c.698-162insT Arg337Cys / Damaging / No N Coupound het 47 F/42 34.8 2 GB/SB 2 c.1201A > G c.27_28delCT Lys401Glu Cys10Profs*16 Tolerable Damaging No 4/6 Compound het 48 M/25 39 2 N 0 c.1224T > G c.1091G > A His408Gln Arg364Gln Damaging Tolerable No N Compound het 49 M/28 76.4 4 EB/SB/GB 5 c.1009C > T c.1270G > T Arg337Cys Val384Phe Damaging Damaging No N Compound het 50 F/37 28.2 2 MN 2 c.698-162insT c.1009C > T / Arg337Cys / Damaging No N Compound het 51 F/25 33.7 2 EP/SB 3 c.479A > T c.1224T > G Gln160Leu His408Gln Damaging Damaging No 3/5 Compound het 52 M/56 36.3 5 N 0 c.985T > C c.1165T > G Ser329Pro Cys389Gly Damaging Damaging No 2/4 Compound het 53 F/46 35.6 2 MN/PPH/PB 5 c.1090C > T c.1165T > G Arg364Trp Cys389Gly Damaging Damaging Yes N Compound het 54 M/48 34 2 N 0 g.11895C > T c.1317G > T c.805 + 120C > T Arg439Ser / Damaging No N Compound het 55 M/30 35.7 4 GB/EB/PB 4 c.1009C > T c.27_28delCT Arg337Cys Cys10Profs*16 Damaging Damaging No N Compound het 56 F/14 19.5 6 N 0 c.1201A > G c.910G > A Lys401Glu Ala304Thr Tolerable No N Compound het 57 F/20 13.9 7 GI-MA 3 c.1091G > A / Arg364Gln Cys10Profs*16 Tolerable No N Compound het 58 F/26 21.1 8 N 0 c.1165T > G c.1224T > G Cys389Gly His408Gln Damaging Damaging No N Compound het 59 F/46 33.1 2 MN 1 c.722C > A c.1261_1261delA Thr241Asn Ile421Ser*fs76 Damaging Damaging No 3/5 Compound het Reference range 11.3-14.5s 72%-133% N N N N N N N N N 2.2 Blood Samples From 2010 to 2024, we collected peripheral venous blood samples in standard 129 mmol/L trisodium citrate tubes from 85 individuals suspected of having inherited FⅦ deficiency, along with 100 healthy controls. After centrifugation at 3000 rpm for 15 minutes at 8°C, Platelet-Poor Plasma and blood cells were obtained. PPP was utilized for coagulation tests, and human genomic DNA was extracted from leukocytes using the TIANamp Genomic DNA Kit (TIANGEN, Beijing, China), following the manufacturer's instructions. 2.3 Coagulation assays The prothrombin time (PT), activated partial thromboplastin time (APTT), FⅦ:C, coagulation factor Ⅱ activity (FⅡ:C), coagulation factor Ⅴ activity (FⅤ:C), coagulation factor Ⅹ activity (FⅩ:C) and Lupus anticoagulant (LA) were determined by a coagulation assay on the STAR analyzer (STAGO, France) using matched commercially available kits. All of them were determined by one-step clotting method. The reference ranges of these indexes in our laboratory were established with 100 healthy subjects. 2.4 Genetic Analysis The F7 gene, including all exons and adjacent intronic regions near splice sites, was amplified on an ABI Thermocycler 2720r (Applied Biosystems, California, USA), following procedures and materials as previously described [ 13 ]. The amplification products were identified and sequenced by Saiheng Bio-Technology Corporation (Shanghai, China). Sequencing results were compared with the F7 gene sequence published in the NCBI database (GenBank: AK298404.1) using Chromas software. PyMOL software was utilized to analyze and predict the effect of amino acid changes on the three-dimensional spatial structure of the FVII protein. Crystal structure data for the FVII protein can be accessed from the Protein Data Bank at https://www.rcsb.org/ (PDB ID: 1F7E). 2.5 Statistical Analysis and Allelic Frequencies In this study, both Pearson correlation and Chi-squared tests were used to assess the relationships and associations between variables. All statistical analyses were performed using Python, and significance was determined at the 0.05 level. Allele frequencies were calculated based on genotype data obtained from the sample population. Exon proportions were determined by analysing the sequence data. 3 RESULTS 3.1 Clinical Phenotype of 85 Patients Eighty-five probands (47 females and 38 males) aged between 7 and 79 years, were enrolled in the study. All probands exhibited significantly reduced plasma FVII levels; specifically, 57 patients had FVII:C < 5%, while the remainder had FVII:C levels below 72%. Levels of FII:C, FV:C, FX:C, and LA were within normal ranges for all patients. The patients had a mean age of 46 years, an average FVII level of 12.13%, and a mean PT level of 25.0 seconds. Thirty-nine parobands presented with various bleeding symptoms. The most common manifestations were gingival bleeding (16%), epistaxis (14%), subcutaneous bleeding (12%), and menorrhagia (12%). Additional symptoms included postoperative bleeding (8%), postpartum hemorrhage (6%), gastrointestinal melena (4%), easy bruising (4%), and hematuria (2%). Bleeding scores in these patients ranged from 0 to 7, as listed in Table 1 . In total, five probands were administered fresh frozen plasma or recombinant activated coagulation factor VIIa (rFVIIa) as a treatment option. Among them, probands 1, 18, 31, and 38 showed improvement in bleeding symptoms. Unfortunately, proband 17, who had intracranial bleeding (ICB), died despite receiving treatment. The remaining 46 probands showed no signs of abnormal bleeding. 3.2 Genotypes of 85 patients In this study, a total of 25 variants were identified, with four variants (p.Trp344Gly, p.Leu170*, p.Gln160Leu, and p.Ser329Pro) being first reported by our team. Additionally, the variant p.Ile421Serfs*76 was reported globally for the first time. Goodeve, Reitsma, and McVey[ 14 ] numbered all residues using the Human Genome Variation Society (HGVS) nomenclature. The starting methionine of the reference protein sequence (NP_000122.1) was numbered as + 1, which may differ from the conventional numbering of + 60, leading to the formation of disulfide-bonded double-stranded molecules. Variants were found throughout the structural domain of the protein encoded by the F7 gene (Fig. 1 ), with introns and splice sites are not depicted in Fig. 1 . Nineteen missense variants were identified, distributed across the Peptide S1, Signal, and Propep structural domains. Furthermore, the exon distribution of the variants was quantified, as illustrated in Fig. 2 . Out of the 59 probands with variants, 14 unrelated families had the p.Arg364Gln variant, 14 had the p.His408Gln variant, 10 had the p.Arg337Cys variant, 9 had p.Cys389Gly variant, and 9 had the p.Cys10Profs*16 variant. These five variants are prevalent variant sites in the Chinese population (Data source: https://www.ensembl.org/index.html ). Additionally, four families had the p.Arg413Gln variant, three unrelated families had the IVS6 + 1G > T, c.698-162insT, and p.Arg364Trp variants, and two unrelated families had the p.Thr241Asn variant. The remaining 13 variants were each found only once. All variants occur at amino acid positions within a signal peptide. 3.3 Analysis of Protein Structure and ACMG The four missense variants and a nonsense variant identified by our reserch group were analyzed for protein modeling using PyMOL (Fig. 3 ). The analysis revealed that all four missense variants and one nonsense variant induced conformational changes in the FVII protein. Specifically, two of the missense variants (p.Gln160Leu, p.Ser329Pro) were found to reduce hydrogen bonding. ACMG analysis yielded the following conclusions: p.Trp344Gly was classified as possibly pathogenic (PS1 + PM2 + PP3); p.Leu170* was identified as pathogenic (PVS1 + PM2); p.Gln160Leu was classified as possibly pathogenic (PS1 + PM2 + PP3); p.Ser329Pro was deemed possibly pathogenic (PM1 + PM2 + PP3); and p.Ile421Serfs*76 was determined to be pathogenic (PVS1 + PM2). The meanings of the relevant abbreviations are explained in the Abbreviations section. 3.4 Statistical Analysis and Allelic Frequencies A chi-square test was conducted to evaluate the association between FVII:C levels (below or above 30%) and the occurrence of bleeding manifestations. The test yielded a Chi-square statistic (χ²), which is defined as follows: The test yielded a Chi-square statistic (χ²) of 5.302, with a p-value of 0.0213 and degrees of freedom (dof) of 1. The p-value is less than the conventional threshold of 0.05, indicating a statistically significant association. Pearson's rank correlation test indicated a correlation coefficient of -0.496 (P = 0.000) between FVII activity and PT, -0.266 (P = 0.014) between FVII activity and haemorrhage score, and 0.149 (P = 0.175) between PT and haemorrhage score. The correlations between the first two variables were statistically significant, particularly the relationship between PT and FVII:C, which was highly significant. Conversely, the correlation between PT and haemorrhage score was not statistically significant, suggesting that the observed relationship may have been due to chance. The p.Arg364Gln and p.His408Gln variants were the most prevalent, collectively representing 18.37% of the total number of alleles. The Cys10Profs*16 and Arg337Cys variants were also relatively common, collectively accounting for 14.29% of the total number of alleles. The remaining variants exhibited intermediate- and low-frequency distributions(Table 2 ). Table 2 Statistics on the Number of Occurrences and Frequencies of FVII Mutant Alleles in the Study Population Mutaion Count Frequency Ala251Val 1 0.010204082 Ala304Thr 1 0.010204082 Arg337Cys 14 0.142857143 Arg364Gln 18 0.183673469 Arg364Trp 3 0.030612245 Arg413Pro 1 0.010204082 Arg439Ser 1 0.010204082 Cys10Profs*16 14 0.142857143 Cys389Gly 10 0.102040816 Gln160Leu 1 0.010204082 His408Gln 18 0.183673469 IVS1a + 5G > A 1 0.010204082 IVS5-1G > A 2 0.020408163 IVS6 + 1G > T 3 0.030612245 Ile421Ser*fs76 1 0.010204082 Leu170* 1 0.010204082 Lys401Glu 3 0.030612245 Ser329Pro 1 0.010204082 Thr241Asn 1 0.010204082 Trp344Gly 1 0.010204082 Val384Phe 1 0.010204082 c.805 + 120C > T 1 0.010204082 4 DISCUSSION As of now, the HGMD variant database ( https://www.hgmd.cf.ac.uk/ac/validate.php ) has identified 397 variants in the F7 gene, including 261 missense/nonsense variants, which account for 65.7% of the total. Through direct sequencing, we identified pathogenic variants in 39 registered symptomatic cases. However, no variants were identified in 6 symptomatic cases and 20 asymptomatic cases. While direct sequencing offers benefits such as low cost, high accuracy, and a short detection period, it may miss cryptic variants, including heterozygous large deletions or insertions, deep intronic variants, or variants in the promoter region. Furthermore, pathogenic variants were identified in 46 asymptomatic registered cases suggesting that a significant proportion of FVII-deficient patients may remain undetected due to methodological limitations and variability in symptoms. Therefore, the actual number of patients with FVII deficiency disorders may be considerably higher than currently recognized. In this study, 25 types of variants were identified in 85 patients with FVII deficiency, with 73.9% occurring in the Peptide S1 region, the main variant-prone area of the F7 gene, and the remaining 26.1% scattered in the Signal peptide, Propeptide, and EGF like-2 regions. The variants included 27 homozygous and 32 compound heterozygous variants, with 14 missense variants accounting for approximately 60.9% of the total, findings that align with the variant database. Approximately 45.45% of the variants were identified in exon 8, indicating that this exon is a major hotspot for variants. This indicates that Exon 8 plays a pivotal role in the gene's functionality, and variants within this region may significantly impact gene functionality. In the context of genetic testing, it is of paramount importance to focus on regions with a high prevalence of variants, with particular emphasis on Exon 8. Prioritising these areas will enhance the accuracy of identifying gene-related variants, thereby improving the sensitivity and specificity of the tests. This approach also provides a robust basis for subsequent functional studies. Five prevalent variants (p.His408Gln, p.Arg364Gln, p.Cys389Gly, p.Cys10Profs*16, and p.Arg337Cys) were identified in unrelated Chinese families, with the p.His408Gln variant, found in approximately 16% of patients when blood relatives were not present. Current data suggest that p.His408Gln induced low FVII does not prevent the development of VTE[ 15 ], although clinical manifestations varied considerably among individuals. The p.Arg364Gln variant, located in a CpG dinucleotide hotspot, affects FVII binding to TF, thereby impacting FX activation[ 16 ]. The p.Cys389Gly variant disrupts the disulfide bond between p.Cys370 and p.Cys389, affecting protein stability and function, with cases showing a range of presentations from asymptomatic to severe[ 17 ]. While primarily associated with non-severe bleeding, rare cases with additional coagulation factor deficiencies (e.g., FX) can lead to lifelong severe bleeding[ 18 ]. The p.Cys10Profs16 variant results in a frameshift and premature stop codon, likely resulting in a nonfunctional protein, which may be associated with severe bleeding symptoms. The p.Arg337Cys variant affects the protein's structure and function, and cases with this variant may also exhibit a wide range of clinical manifestations, from mild to severe bleeding. We also identified five missense/nonsense variants, including one novel variant and four previously reported by our group. The p.Ser329Pro variant was associated with hemoptysis and resolved with treatment. The p.Gln160Leu variant was linked to recurrent epistaxis, while the p.Leu170* variant was associated with prolonged menstrual symptoms. In both cases, the bleeding symptoms resolved spontaneously without the need for haemostatic treatment. One patient had severe bleeding with a heterozygous p.Trp344Gly variant, while another patient experienced hematuria for over two weeks with a homozygous p.Trp344Gly variant. Further genetic analysis indicated that clinical phenotypes cannot be solely attributed to these variants, suggesting potential interactions with other genetic or environmental factors. ACMG analyses classified these variants as possibly pathogenic or pathogenic. The bleeding tendency linked with FVII deficiency can manifest in various ways, ranging from more severe than hemophilia to very mild or even asymptomatic cases. In the study, only 39 out of 85 patients with FVII deficiency experienced bleeding, with excessive menstrual bleeding being the most prevalent symptom among the women. Studies on FVII deficiency have suggested that the reduction in FVII:C may not be associated with bleeding manifestations[ 15 ]. However, a statistical analysis of the study cohort yielded markedly different results. The chi-square test demonstrated that there is a notable increase in the likelihood of bleeding when FVII:C levels reach a very low point. Pearson's test revealed a statistically significant correlation between FVII:C and both PT and bleeding score. Specifically, there was a statistically significant inverse relationship between PT and FVII:C, with PT demonstrating a decrease as FVII:C increased. Furthermore, a higher FVII:C was associated with a lower bleeding score, although this relationship was weaker and still statistically significant. Conversely, no statistically significant correlation was observed between PT and bleeding score, suggesting that any observed relationship between these two variables may be coincidental. These findings underscore the importance of FVII:C levels in influencing PT and haemorrhage risk, while highlighting the need for further investigation into the factors affecting bleeding scores. A review of the allele frequencies revealed that the Arg364Gln and His408Gln variants were the most prevalent in the study population. This indicates a significant prevalence of these variants in the study population, which suggests that they may be of high genetic importance or health relevance in this population. Further investigation is required to elucidate the significance of these high-frequency variants. The high frequency of these variants may be associated with specific molecular mechanisms that may have important implications for the pathogenesis of the disease. Future studies should concentrate on investigating the specific functions of these variants in molecular mechanisms, examining their association with related diseases, and exploring their potential for therapeutic applications. FVII plays a crucial role in the exogenous coagulation pathway, and managing congenital FVII deficiency presents a challenge in accurately assessing bleeding risk. Therefore, FVII preparations are currently the preferred treatment option due to their effectiveness and low risk of blood-borne infections[ 19 ]. Recombinant technology offers an effective method for large-scale production of human FVII, accompanied by complex post-translational modifications. Various recombinant expression systems have been established in recent years[ 20 ], ensuring proper protein folding, accurate post-translational modifications, and correct glycosylation sites. These factors are crucial for maintaining the stability of recombinant proteins, particularly those containing complex disulfide bonds or post-translational modifications. It is hoped that the study of FVII will serve as a reference for the future development in recombinant human FVII using a recombinant expression system[ 21 ]. 5 CONCLUSION This study presents the variant spectrum of FVII deficiency in a southeastern Chinese population, highlighting significant correlations between FVII:C levels and clinical outcomes. The highest allele frequencies were observed in p.Arg364Gln, p.His408Gln, p.Arg337Cys, p.Cys10Profs*16, and p.Cys389Gly, with p.Arg364Gln being the most predominant, suggesting a potential founder effect. The presence of asymptomatic individuals with low FVII:C levels indicates that the prevalence of FVII deficiency may be underestimated. Therefore, comprehensive genetic screening is essential to accurately understand genotype-phenotype correlations. Such screening will improve diagnostic accuracy and inform better management strategies for FVII deficiency in the Chinese population. Declarations Declarations Ethics approval and consent to participate The study received approval from the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University (KY2022-R193). All participants provided written informed consent prior to their involvement in the study. Consent for publication Not applicable. Competing interests All the authors declare no conflicts of interest. Funding We would like to acknowledge the support provided by the Wenzhou Basic Medical and Health Science and Technology Project (Y20220125) and the Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province (2022E10022) for this work. Author Contributions LY analyzed data and wrote the manuscript. LQ, SW, YJ, and LY collected the raw data. JP and LY provided advices on interpretation of the results. MW and YX critically reviewed and revised the manuscript. All authors read and approved the final manuscript. Acknowledgements The authors express their gratitude to the patients and their family members for their cooperation. They declare no interests that could be perceived as posing a conflict or bias. Availability of data and material All data generated or analyzed during this study are included in this published article. Additional data used in the current study are not publicly available due to privacy restrictions but can be obtained from the corresponding authors upon reasonable request. Please contact Yaosheng Xie (email: [email protected] ) or Mingshan Wang (email: [email protected] ) for access to the datasets. References Alexander B, Goldstein R, Landwehr G, Cook CD. Congenital spca deficiency: A hitherto unrecognized coagulation defect with hemorrhage rectified by serum and serum fractions. J Clin Invest. 1951;30(6):596–608. https://doi.org/10.1172/jci102477 . Bernardi F, Mariani G. Biochemical, molecular and clinical aspects of coagulation factor vii and its role in hemostasis and thrombosis. Haematologica. 2021;106(2):351–62. https://doi.org/10.3324/haematol.2020.248542 . Levi M. Disseminated intravascular coagulation in cancer: An update. Semin Thromb Hemost. 2019;45(4):342–47. https://doi.org/10.1055/s-0039-1687890 . Elango K, Javaid A, Khetarpal BK, Ramalingam S, Kolandaivel KP, Gunasekaran K, et al. The effects of warfarin and direct oral anticoagulants on systemic vascular calcification: A review. Cells. 2021;10(4). https://doi.org/10.3390/cells10040773 . Cassel A, Rosenberg N, Muhammad E, Livnat T, Dardik R, Berl M, et al. Novel mutation in coagulation factor vii (carmel mutation): Identification and characterization. Res Pract Thromb Haemost. 2021;5(4):e12407. https://doi.org/10.1002/rth2.12407 . Pshenichnikova O, Selivanova D, Shchemeleva E, Abramova T, Zozulya N, Surin V. Molecular genetic analysis of russian patients with coagulation factor fvii deficiency. Genes (Basel). 2023;14(9). https://doi.org/10.3390/genes14091767 . McVey JH, Boswell E, Mumford AD, Kemball-Cook G, Tuddenham EG. Factor vii deficiency and the fvii mutation database. Hum Mutat. 2001;17(1):3–17. https://doi.org/10.1002/1098-1004(2001)17:13.0.Co;2-v . Ravanbod S, Faranoush M, Changi-Ashtiani M, Rokni-Zadeh H, Shahani T. Extensive genetic screening of iranian factor fvii-deficient individuals unraveled several novel mutations and postulated founder effects in some cases. Res Pract Thromb Haemost. 2023;7(1):100003. https://doi.org/10.1016/j.rpth.2022.100003 . Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the american college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17(5):405–24. https://doi.org/10.1038/gim.2015.30 . Giansily-Blaizot M, Rallapalli PM, Perkins SJ, Kemball-Cook G, Hampshire DJ, Gomez K, et al. The eahad blood coagulation factor vii variant database. Hum Mutat. 2020;41(7):1209–19. .https://doi.org/10.1002/humu.24025 . Ellingford JM, Ahn JW, Bagnall RD, Baralle D, Barton S, Campbell C, et al. Recommendations for clinical interpretation of variants found in non-coding regions of the genome. Genome Med. 2022;14(1):73. https://doi.org/10.1186/s13073-022-01073-3 . Mohsenian S, Palla R, Menegatti M, Cairo A, Lecchi A, Casini A, et al. Congenital fibrinogen disorders: A retrospective clinical and genetic analysis of the prospective rare bleeding disorders database. Blood Adv. 2024;8(6):1392–404. https://doi.org/10.1182/bloodadvances.2023012186 . Luo S, Liu S, Xu M, Li X, Zhang H, Jin Y, et al. Analysis of phenotype and genotype of a family with hereditary coagulation factor v deficiency caused by the compound heterozygous mutations. Blood Coagul Fibrinolysis. 2020;31(7):485–89. https://doi.org/10.1097/mbc.0000000000000946 . Goodeve AC, Reitsma PH, McVey JH. Nomenclature of genetic variants in hemostasis. J Thromb Haemost. 2011;9(4):852. 5.https://doi.org/10.1111/j.1538-7836.2011.04191.x . Lou C, Jiang J, Chen W, Zhang Z, Xu G, Liu Y, et al. Structural and functional characterization of novel f7 mutations identified in chinese factor vii-deficient patients. Br J Haematol. 2023;202(3):623–35. https://doi.org/10.1111/bjh.18768 . Peters SC, Childers KC, Mitchell CE, Avery NG, Reese SS Jr., Mitchell C, et al. Stable binding to phosphatidylserine-containing membranes requires conserved arginine residues in tandem c domains of blood coagulation factor viii. Front Mol Biosci. 2022;9:1040106. https://doi.org/10.3389/fmolb.2022.1040106 . Alesci RS, Hecking C, Racké B, Janssen D, Dempfle CE. Utility of acmg classification to support interpretation of molecular genetic test results in patients with factor vii deficiency. Front Med (Lausanne). 2023. 10:1220813.https://doi.org/10.3389/fmed.2023.1220813 . Menegatti M, Karimi M, Garagiola I, Mannucci P, Peyvandi F. A rare inherited coagulation disorder: Combined homozygous factor vii and factor x deficiency. Am J Hematol. 2004;77(1):90–1. https://doi.org/10.1002/ajh.20132 . Szczepanik A, Wiszniewski A, Oses-Szczepanik A, Dąbrowski W, Pielaciński K, Misiak A. Surgery in patients with congenital factor vii deficiency - a single center study. Pol Przegl Chir. 2018;90(5):1–5. https://doi.org/10.5604/01.3001.0012.0668 . Khan SU, Khan MU, Suleman M, Inam A, Din MAU. Hemophilia healing with aav: Navigating the frontier of gene therapy. Curr Gene Ther. 2024;24(4):265–77. https://doi.org/10.2174/0115665232279893231228065540 . Walsh G. Biopharmaceutical benchmarks 2018. Nat Biotechnol. 2018;36(12):1136. 45.https://doi.org/10.1038/nbt.4305 . Unsectioned Paragraphs Running title: Spectrum of Variants in the F7 Gene Abbreviations FVII Coagulation factor VII FVII:C Coagulation factor VII activity ICH Including intracranial hemorrhage ELISA Enzyme-linked immunosorbent assay PCR Polymerase chain reaction PT Prothrombin time APTT Activated partial thromboplastin time FⅡ:C Coagulation factor Ⅱ activity FⅤ:C Coagulation factor Ⅴ activity FⅩ:C Coagulation factor Ⅹ activity LA Lupus anticoagulant GB Gingival bleeding EP Epistaxis SB Subcutaneous bleeding MN Menorrhagia PB Postoperative bleeding PPH Postpartum Hemorrhage GI-MA Gastrointestinal Melena EB Easy to bruise HU Hematuria SDH Subdural haematoma N No bleeding F Female M Man Supplementary Files SupplementaryTable1.docx SupplementaryTable2.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4674402","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":334598857,"identity":"ba8e37a9-ee6b-4693-af3c-24163dcef745","order_by":0,"name":"Longying Ye","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABB0lEQVRIie3RsUoDMRjA8RyBm74za44W9BECB5Zisa9yh1AXB0enkhLIJM7Xzadw/kLALoe3HnTQoy9w3USq9Cqck+Q6CuY/hJDkRwghxOf7k1F5GKGdIDZ3E2BM9pGgI2FW58VsGOd4HDmoJIm0nQiZuoFYLRab2w87HLHHcw5hCYJg0GxvHKQwKlk+WBjnbzPOYQ0jKmm8fHKQKtOD6N6CqPCZC76GscSQRi7yWnfEaJ6KFxCY9pAq0AN4b0mpaHsa+0lcZCqJ5HV7SxjUEq8gzo1yvuVkZc0GdhdTUZaN/fy6nDKmTLN1kDNsh0ArQnjarf381O+dfm/v5oQwdB70+Xy+f9weT/NcjVUVjxwAAAAASUVORK5CYII=","orcid":"","institution":"The First Affiliated Hospital of Wenzhou Medical University","correspondingAuthor":true,"prefix":"","firstName":"Longying","middleName":"","lastName":"Ye","suffix":""},{"id":334598858,"identity":"564d347c-1b71-4384-be29-15f4be327c8a","order_by":1,"name":"Langyi Qin","email":"","orcid":"","institution":"The First Affiliated Hospital of Wenzhou Medical University","correspondingAuthor":false,"prefix":"","firstName":"Langyi","middleName":"","lastName":"Qin","suffix":""},{"id":334598859,"identity":"f4c9042a-29f4-444a-8334-653316c3bf5c","order_by":2,"name":"Saifang Wang","email":"","orcid":"","institution":"The First Affiliated Hospital of Wenzhou Medical University","correspondingAuthor":false,"prefix":"","firstName":"Saifang","middleName":"","lastName":"Wang","suffix":""},{"id":334598860,"identity":"09c5c6a4-f6bc-4122-a6e2-ff7efe34b4cf","order_by":3,"name":"Yanhui Jin","email":"","orcid":"","institution":"The First Affiliated Hospital of Wenzhou Medical University","correspondingAuthor":false,"prefix":"","firstName":"Yanhui","middleName":"","lastName":"Jin","suffix":""},{"id":334598861,"identity":"19a8ec0b-c237-4d03-83b5-2213e15872ad","order_by":4,"name":"Lihong Yang","email":"","orcid":"","institution":"The First Affiliated Hospital of Wenzhou Medical University","correspondingAuthor":false,"prefix":"","firstName":"Lihong","middleName":"","lastName":"Yang","suffix":""},{"id":334598862,"identity":"15d70415-6e31-4f1b-b68e-ab7efc43667a","order_by":5,"name":"Mingshan Wang","email":"","orcid":"","institution":"The First Affiliated Hospital of Wenzhou Medical University Department of Gynecology","correspondingAuthor":false,"prefix":"","firstName":"Mingshan","middleName":"","lastName":"Wang","suffix":""},{"id":334598863,"identity":"89f80901-87c3-4e25-a054-3acec5c9eee4","order_by":6,"name":"Yaosheng Xie","email":"","orcid":"","institution":"The First Affiliated Hospital of Wenzhou Medical University Department of Gynecology","correspondingAuthor":false,"prefix":"","firstName":"Yaosheng","middleName":"","lastName":"Xie","suffix":""}],"badges":[],"createdAt":"2024-07-02 12:59:18","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4674402/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4674402/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":64007204,"identity":"e656ce9d-1fcc-4481-a5c1-1890484e4193","added_by":"auto","created_at":"2024-09-04 21:56:44","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":128114,"visible":true,"origin":"","legend":"\u003cp\u003eA schematic diagram of the structural domains and associated variant sites of the FVII protein.\u003c/p\u003e","description":"","filename":"Fig1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4674402/v1/3eb9d5543918eaee889289ee.jpg"},{"id":64007587,"identity":"da3c197a-3545-4340-96e9-fa5b3fae07fe","added_by":"auto","created_at":"2024-09-04 22:04:44","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":248951,"visible":true,"origin":"","legend":"\u003cp\u003eDistribution of variants in different exons and introns of the \u003cem\u003eF7 \u003c/em\u003egene.\u003c/p\u003e","description":"","filename":"Fig2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4674402/v1/faf3c21802ee2473d7b3682b.jpg"},{"id":64007586,"identity":"85eea29e-bd17-47d0-a214-f31193dbef28","added_by":"auto","created_at":"2024-09-04 22:04:43","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":223298,"visible":true,"origin":"","legend":"\u003cp\u003eStructural Map of FVII Protein Highlighting Four variants: p.Gln160Leu, p.Leu170*, p.Ser329Pro, and p.Trp344Gly\u003c/p\u003e","description":"","filename":"Fig3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4674402/v1/8656475a3d710786746ee122.jpg"},{"id":66039603,"identity":"076b958c-9d72-4730-86eb-9c4b80670498","added_by":"auto","created_at":"2024-10-07 05:37:33","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1640118,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4674402/v1/a27a8ce4-7cf8-4ce0-993f-990e4c8bf259.pdf"},{"id":64007206,"identity":"debbbb5d-c8e1-4144-9dfa-4c8761a91ed9","added_by":"auto","created_at":"2024-09-04 21:56:44","extension":"docx","order_by":10,"title":"","display":"","copyAsset":false,"role":"supplement","size":15953,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryTable1.docx","url":"https://assets-eu.researchsquare.com/files/rs-4674402/v1/2066eb80a79ecbd991e08cf9.docx"},{"id":64007208,"identity":"19857d17-87c5-4015-9e5b-848b0db7101e","added_by":"auto","created_at":"2024-09-04 21:56:44","extension":"docx","order_by":11,"title":"","display":"","copyAsset":false,"role":"supplement","size":13961,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryTable2.docx","url":"https://assets-eu.researchsquare.com/files/rs-4674402/v1/e6183f42e7959ee0522bf888.docx"}],"financialInterests":"","formattedTitle":"Recurrent Founder Variant in Inherited FVII Deficiency: Molecular Spectrum Analysis in Southeast China Recurrent Founder Variant in Inherited FVII Deficiency: Molecular Spectrum Analysis in Southeast China","fulltext":[{"header":"1 INTRODUCTION","content":"\u003cp\u003eFactor VII (FVII) (OMIM: 227500) is a key factor in the initiation of coagulation. FVII deficiency initially reported by B. Alexander et al. in 1951[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e], is a rare congenital bleeding disorder characterized by low or undetectable plasma levels of FVII, affecting approximately 1 in 500,000 people worldwide[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. It is caused by variants in the \u003cem\u003eF7\u003c/em\u003e gene located in the 13q34 region of the human chromosome. Patients with the disease exhibit reduced FVII activity (FVII:C) in plasma, with clinical bleeding symptoms varying greatly from asymptomatic to severe[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. The severity of clinical manifestations is closely linked to the number, location, and functional impact of the gene variants[\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. However, there is a close connection between the number of gene variants, their locus, and their impact on function[\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. Variants leading to the complete absence of active plasma FVII are linked to severe phenotypes, such as neonatal death or irreversible organ damage, including intracranial hemorrhage (ICH)[\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. However, even trace amounts of active protein, adequate to initiate coagulation, markedly influence the phenotype[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. This is particularly true when genetic information is combined with relevant clinical data and modeling analyses, aiding in determining the pathogenicity of a variant[\u003cspan additionalcitationids=\"CR10\" citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe FVII Variant Database (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.hgmd.cf.ac.uk/docs/login.html\u003c/span\u003e\u003cspan address=\"https://www.hgmd.cf.ac.uk/docs/login.html\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e) has cataloged over 200 variants in the \u003cem\u003eF7\u003c/em\u003e gene, primarily identified through small patient studies and individual case reports. This extensive database provides valuable insights into the genetic diversity and pathogenic mechanisms underlying FVII deficiency.\u003c/p\u003e \u003cp\u003eIn this study, additional genetic profiles can enhance our understanding of genotype-phenotype correlations in this rare coagulation disorder. We conducted a comprehensive analysis of variants and clinical presentations in 85 probands diagnosed with FVII deficiency, along with their respective relatives from the Chinese population. The data were collected over a fourteen-year period from 2010 to the present at the First Affiliated Hospital of Wenzhou Medical University. Genetic counseling was offered to other relatives upon identification of one or more variants in a family.\u003c/p\u003e \u003cp\u003eThe objective of this study was to investigate the correlation between genotype and phenotype and to summarize the specific variant spectrum of the \u003cem\u003eF7\u003c/em\u003e gene in 85 patients with FVII deficiency from the Chinese population.\u003c/p\u003e"},{"header":"2 MATERIALS AND METHODS","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003e2.1 Participants\u003c/h2\u003e \u003cp\u003e The retrospective cohort study was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. A total of 85 unrelated probands (FVII:C\u0026thinsp;\u0026lt;\u0026thinsp;72% ) from 2010 to 2024 in our study provides a reasonable sample size to investigate FVII deficiency. The parents of probands numbered 1, 3, 6, 7, 8, 12\u0026ndash;15, 24, and 25 are consanguineous (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). The patient's demographic details, including age, sex, bleeding history, and consanguinity, were duly recorded. Exclusion criteria included a history of hepatic and renal disease, as well as acquired FVII defects. Among the population with detected variants, 66.1% exhibited symptoms indicative of bleeding, while 33.9% did not demonstrate any such symptoms. Other platelet or coagulation factor defects were also excluded. Bleeding scores of 85 patients were calculated according to ISTH-BAT, a bleeding assessment tool that Rodeghiero introduced[\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. The normal ranges for bleeding scores are 0\u0026ndash;3 for adult males and 0\u0026ndash;5 for adult females. The FⅦ levels were measured before transfusion. Other platelet or coagulation defects were excluded. Details of patients with detected variants are presented in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e, whilst information of patients without detected variants is provided in Supplementary Table\u0026nbsp;1. The reference sequences table is included in Supplementary Table\u0026nbsp;2 (both supplementary tables are available as separate files)\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eLaboratory Findings and Clinical Phenotypes of Patients with Mutated FVII Deficiency. \u003cb\u003eNote\u003c/b\u003e: The meaning of all abbreviations has been previously indicated.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"12\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c10\" colnum=\"10\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c11\" colnum=\"11\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c12\" colnum=\"12\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSr.no\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGender/Age\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePT(s)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFⅦ:C(%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eBleeding\u003c/p\u003e \u003cp\u003emanifestation\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eBleeding score\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNucleotide change\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c8\"\u003e \u003cp\u003eMature protein\u003c/p\u003e \u003cp\u003ealteration\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c9\"\u003e \u003cp\u003ePredicted pathogenicity\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c10\"\u003e \u003cp\u003eConsanguinity\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c11\"\u003e \u003cp\u003ecarriers/families\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c12\"\u003e \u003cp\u003eZygosity\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e1\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e30.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eSB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1224T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eHis408Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e3/6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e2\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM/7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e32.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ePB/EP/SB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.27_28delCT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eCys10Profs*16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e2/5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e3\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM/41\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e35.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1090C\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg364Trp\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e2/4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e4\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e26.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.27_28delCT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eCys10Profs*16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e5\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM/53\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e34\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eGB/PB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1090C\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg364Trp\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e6\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM/38\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e37.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eEB/EP/HU\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1030T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eTrp344Gly\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e5/7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e7\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/27\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e31.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eEP/MN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1090C\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg364Trp\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e8\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/55\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e36.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eGB/SB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1091G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg364Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eTolerable\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e9\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e20.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1009C\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg337Cys\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e3/4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e10\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/70\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e38.7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1091G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg364Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eTolerable\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e11\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/67\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e30.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1091G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg364Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eTolerable\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e12\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM/36\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e32.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1091G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg364Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eTolerable\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e13\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e42.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eGB/PB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1091G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg364Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eTolerable\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e14\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM/48\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e30.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eEP\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1224T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eHis408Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e3/5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e15\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM/57\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e33.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1091G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg364Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eTolerable\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e16\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/48\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e39.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1165T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eCys389Gly\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e3/6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e17\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM/56\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e30.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eICB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.722C\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eThr241Asn\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e3/4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e18\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e39.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1224T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eHis408Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e19\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM/75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e36.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1165T\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eCys389Gly\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e20\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/53\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e53.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1009C\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg337Cys\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e21\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/54\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e34.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1091G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg364Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eTolerable\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e3/5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e22\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM/75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e27.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.27_28delCT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eCys10Profs*16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e23\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM/35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e36.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1091G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg364Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eTolerable\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e24\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM/32\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e26.7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.910G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eAla304Thr\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e2/4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e25\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/31\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e20.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eGB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1009C\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg337Cys\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e26\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003em/28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e28.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eMN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1009C\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg337Cys\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e27\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003em/54\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e32.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eGI-MA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1091G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg364Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eTolerable\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eHomo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e28\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/56\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e37.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eGB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e/\u003c/p\u003e \u003cp\u003ec.1165T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eIVS6\u0026thinsp;+\u0026thinsp;1G\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003cp\u003eCys389Gly\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e/\u003c/p\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e29\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/47\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e25.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eIVS1a\u0026thinsp;+\u0026thinsp;5G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003cp\u003eIVS6\u0026thinsp;+\u0026thinsp;1G\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e/\u003c/p\u003e \u003cp\u003e/\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e30\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/57\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e31.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eGB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1165T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003cp\u003ec.1224T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eCys389Gly\u003c/p\u003e \u003cp\u003eHis408Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e3/5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e31\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM/67\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e24.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eICB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.27_28delCT\u003c/p\u003e \u003cp\u003ec.1238G\u0026thinsp;\u0026gt;\u0026thinsp;C\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eCys10Profs*16\u003c/p\u003e \u003cp\u003eArg413Pro\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e4/6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e32\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/52\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e19.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.752C\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003cp\u003ec.1165T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eAla251Val\u003c/p\u003e \u003cp\u003eCys389Gly\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e5/7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e33\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM/59\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e32.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eEP\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1165T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003cp\u003ec.1224T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eCys389Gly\u003c/p\u003e \u003cp\u003eHis408Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e34\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e22.7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1009C\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003cp\u003ec.1224T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg337Cys\u003c/p\u003e \u003cp\u003eHis408Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e35\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e27.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1009C\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003cp\u003ec.27_28delCT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg337Cys\u003c/p\u003e \u003cp\u003eCys10Profs*16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e2/4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e36\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM/55\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e39.6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.27_28delCT\u003c/p\u003e \u003cp\u003ec.1091G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eCys10Profs*16\u003c/p\u003e \u003cp\u003eArg364Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003cp\u003eTolerable\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e4/6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e37\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/52\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e19.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eMN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.691-693delTTG\u003c/p\u003e \u003cp\u003ec.1224T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eLeu170*\u003c/p\u003e \u003cp\u003eHis408Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e3/4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e38\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/21\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e36.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eEP/GB/PPH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1201A\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003cp\u003e/\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eLys401Glu\u003c/p\u003e \u003cp\u003eIVS5-1G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eTolerable\u003c/p\u003e \u003cp\u003e/\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e39\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e35.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eMN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1224T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003cp\u003ec.1238G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eHis408Gln\u003c/p\u003e \u003cp\u003eArg413Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e40\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/66\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e21.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eGI-MA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1238G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003cp\u003e/\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg413Gln\u003c/p\u003e \u003cp\u003eIVS6\u0026thinsp;+\u0026thinsp;1 G\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003cp\u003e/\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e41\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/34\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e33.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1091G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003cp\u003ec.1238G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg364Gln\u003c/p\u003e \u003cp\u003eArg413Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eTolerable\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e3/5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e42\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/47\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e36.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eMN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e/\u003c/p\u003e \u003cp\u003ec.1238G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eIVS6\u0026thinsp;+\u0026thinsp;1G\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003cp\u003eArg413Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e/\u003c/p\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e43\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e35.7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eSB/GB/PB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1091G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003cp\u003ec.1224T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg364Gln\u003c/p\u003e \u003cp\u003eHis408Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eTolerable\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e44\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/61\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e38.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eSDH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1224T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003cp\u003e/\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eHis408Gln\u003c/p\u003e \u003cp\u003eIVS5\u0026thinsp;+\u0026thinsp;1G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003cp\u003e/\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e45\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e34.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eGI-MA/GB/EP\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1224T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003cp\u003ec.698-162insT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eHis408Gln\u003c/p\u003e \u003cp\u003e/\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003cp\u003e/\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e3/6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e46\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM/25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e25.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ePPH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1009C\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003cp\u003ec.698-162insT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg337Cys\u003c/p\u003e \u003cp\u003e/\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003cp\u003e/\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCoupound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e47\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/42\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e34.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eGB/SB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1201A\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003cp\u003ec.27_28delCT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eLys401Glu\u003c/p\u003e \u003cp\u003eCys10Profs*16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eTolerable\u003c/p\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e4/6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e48\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM/25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1224T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003cp\u003ec.1091G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eHis408Gln\u003c/p\u003e \u003cp\u003eArg364Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003cp\u003eTolerable\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e49\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM/28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e76.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eEB/SB/GB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1009C\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003cp\u003ec.1270G\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg337Cys\u003c/p\u003e \u003cp\u003eVal384Phe\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e50\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/37\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e28.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eMN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.698-162insT\u003c/p\u003e \u003cp\u003ec.1009C\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e/\u003c/p\u003e \u003cp\u003eArg337Cys\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e/\u003c/p\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e51\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e33.7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eEP/SB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.479A\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003cp\u003ec.1224T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eGln160Leu\u003c/p\u003e \u003cp\u003eHis408Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e3/5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e52\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM/56\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e36.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.985T\u0026thinsp;\u0026gt;\u0026thinsp;C\u003c/p\u003e \u003cp\u003ec.1165T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eSer329Pro\u003c/p\u003e \u003cp\u003eCys389Gly\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e2/4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e53\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/46\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e35.6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eMN/PPH/PB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1090C\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003cp\u003ec.1165T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg364Trp\u003c/p\u003e \u003cp\u003eCys389Gly\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e54\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM/48\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e34\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eg.11895C\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003cp\u003ec.1317G\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003ec.805\u0026thinsp;+\u0026thinsp;120C\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003cp\u003eArg439Ser\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e/\u003c/p\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e55\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM/30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e35.7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eGB/EB/PB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1009C\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003cp\u003ec.27_28delCT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg337Cys\u003c/p\u003e \u003cp\u003eCys10Profs*16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e56\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e19.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1201A\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003cp\u003ec.910G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eLys401Glu\u003c/p\u003e \u003cp\u003eAla304Thr\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eTolerable\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e57\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e13.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eGI-MA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1091G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003cp\u003e/\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eArg364Gln\u003c/p\u003e \u003cp\u003eCys10Profs*16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eTolerable\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e58\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e21.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.1165T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003cp\u003ec.1224T\u0026thinsp;\u0026gt;\u0026thinsp;G\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eCys389Gly\u003c/p\u003e \u003cp\u003eHis408Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e59\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF/46\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e33.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eMN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ec.722C\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003cp\u003ec.1261_1261delA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eThr241Asn Ile421Ser*fs76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003cp\u003eDamaging\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e3/5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eCompound het\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eReference range\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e11.3-14.5s\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e72%-133%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e2.2 Blood Samples\u003c/h2\u003e \u003cp\u003eFrom 2010 to 2024, we collected peripheral venous blood samples in standard 129 mmol/L trisodium citrate tubes from 85 individuals suspected of having inherited FⅦ deficiency, along with 100 healthy controls. After centrifugation at 3000 rpm for 15 minutes at 8\u0026deg;C, Platelet-Poor Plasma and blood cells were obtained. PPP was utilized for coagulation tests, and human genomic DNA was extracted from leukocytes using the TIANamp Genomic DNA Kit (TIANGEN, Beijing, China), following the manufacturer's instructions.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003e2.3 Coagulation assays\u003c/h2\u003e \u003cp\u003eThe prothrombin time (PT), activated partial thromboplastin time (APTT), FⅦ:C, coagulation factor Ⅱ activity (FⅡ:C), coagulation factor Ⅴ activity (FⅤ:C), coagulation factor Ⅹ activity (FⅩ:C) and Lupus anticoagulant (LA) were determined by a coagulation assay on the STAR analyzer (STAGO, France) using matched commercially available kits. All of them were determined by one-step clotting method. The reference ranges of these indexes in our laboratory were established with 100 healthy subjects.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003e2.4 Genetic Analysis\u003c/h2\u003e \u003cp\u003eThe \u003cem\u003eF7\u003c/em\u003e gene, including all exons and adjacent intronic regions near splice sites, was amplified on an ABI Thermocycler 2720r (Applied Biosystems, California, USA), following procedures and materials as previously described [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. The amplification products were identified and sequenced by Saiheng Bio-Technology Corporation (Shanghai, China). Sequencing results were compared with the \u003cem\u003eF7\u003c/em\u003e gene sequence published in the NCBI database (GenBank: AK298404.1) using Chromas software. PyMOL software was utilized to analyze and predict the effect of amino acid changes on the three-dimensional spatial structure of the FVII protein. Crystal structure data for the FVII protein can be accessed from the Protein Data Bank at \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.rcsb.org/\u003c/span\u003e\u003cspan address=\"https://www.rcsb.org/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (PDB ID: 1F7E).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003e2.5 Statistical Analysis and Allelic Frequencies\u003c/h2\u003e \u003cp\u003eIn this study, both Pearson correlation and Chi-squared tests were used to assess the relationships and associations between variables. All statistical analyses were performed using Python, and significance was determined at the 0.05 level. Allele frequencies were calculated based on genotype data obtained from the sample population. Exon proportions were determined by analysing the sequence data.\u003c/p\u003e \u003c/div\u003e"},{"header":"3 RESULTS","content":"\u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003e3.1 Clinical Phenotype of 85 Patients\u003c/h2\u003e \u003cp\u003eEighty-five probands (47 females and 38 males) aged between 7 and 79 years, were enrolled in the study. All probands exhibited significantly reduced plasma FVII levels; specifically, 57 patients had FVII:C\u0026thinsp;\u0026lt;\u0026thinsp;5%, while the remainder had FVII:C levels below 72%. Levels of FII:C, FV:C, FX:C, and LA were within normal ranges for all patients. The patients had a mean age of 46 years, an average FVII level of 12.13%, and a mean PT level of 25.0 seconds.\u003c/p\u003e \u003cp\u003eThirty-nine parobands presented with various bleeding symptoms. The most common manifestations were gingival bleeding (16%), epistaxis (14%), subcutaneous bleeding (12%), and menorrhagia (12%). Additional symptoms included postoperative bleeding (8%), postpartum hemorrhage (6%), gastrointestinal melena (4%), easy bruising (4%), and hematuria (2%). Bleeding scores in these patients ranged from 0 to 7, as listed in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e. In total, five probands were administered fresh frozen plasma or recombinant activated coagulation factor VIIa (rFVIIa) as a treatment option. Among them, probands 1, 18, 31, and 38 showed improvement in bleeding symptoms. Unfortunately, proband 17, who had intracranial bleeding (ICB), died despite receiving treatment. The remaining 46 probands showed no signs of abnormal bleeding.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003e3.2 Genotypes of 85 patients\u003c/h2\u003e \u003cp\u003eIn this study, a total of 25 variants were identified, with four variants (p.Trp344Gly, p.Leu170*, p.Gln160Leu, and p.Ser329Pro) being first reported by our team. Additionally, the variant p.Ile421Serfs*76 was reported globally for the first time. Goodeve, Reitsma, and McVey[\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e] numbered all residues using the Human Genome Variation Society (HGVS) nomenclature. The starting methionine of the reference protein sequence (NP_000122.1) was numbered as +\u0026thinsp;1, which may differ from the conventional numbering of +\u0026thinsp;60, leading to the formation of disulfide-bonded double-stranded molecules. Variants were found throughout the structural domain of the protein encoded by the \u003cem\u003eF7\u003c/em\u003e gene (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e), with introns and splice sites are not depicted in Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e. Nineteen missense variants were identified, distributed across the Peptide S1, Signal, and Propep structural domains. Furthermore, the exon distribution of the variants was quantified, as illustrated in Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e. Out of the 59 probands with variants, 14 unrelated families had the p.Arg364Gln variant, 14 had the p.His408Gln variant, 10 had the p.Arg337Cys variant, 9 had p.Cys389Gly variant, and 9 had the p.Cys10Profs*16 variant. These five variants are prevalent variant sites in the Chinese population (Data source: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.ensembl.org/index.html\u003c/span\u003e\u003cspan address=\"https://www.ensembl.org/index.html\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e). Additionally, four families had the p.Arg413Gln variant, three unrelated families had the IVS6\u0026thinsp;+\u0026thinsp;1G\u0026thinsp;\u0026gt;\u0026thinsp;T, c.698-162insT, and p.Arg364Trp variants, and two unrelated families had the p.Thr241Asn variant. The remaining 13 variants were each found only once. All variants occur at amino acid positions within a signal peptide.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003e3.3 Analysis of Protein Structure and ACMG\u003c/h2\u003e \u003cp\u003eThe four missense variants and a nonsense variant identified by our reserch group were analyzed for protein modeling using PyMOL (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003e). The analysis revealed that all four missense variants and one nonsense variant induced conformational changes in the FVII protein. Specifically, two of the missense variants (p.Gln160Leu, p.Ser329Pro) were found to reduce hydrogen bonding.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eACMG analysis yielded the following conclusions: p.Trp344Gly was classified as possibly pathogenic (PS1\u0026thinsp;+\u0026thinsp;PM2\u0026thinsp;+\u0026thinsp;PP3); p.Leu170* was identified as pathogenic (PVS1\u0026thinsp;+\u0026thinsp;PM2); p.Gln160Leu was classified as possibly pathogenic (PS1\u0026thinsp;+\u0026thinsp;PM2\u0026thinsp;+\u0026thinsp;PP3); p.Ser329Pro was deemed possibly pathogenic (PM1\u0026thinsp;+\u0026thinsp;PM2\u0026thinsp;+\u0026thinsp;PP3); and p.Ile421Serfs*76 was determined to be pathogenic (PVS1\u0026thinsp;+\u0026thinsp;PM2). The meanings of the relevant abbreviations are explained in the Abbreviations section.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003e3.4 Statistical Analysis and Allelic Frequencies\u003c/h2\u003e \u003cp\u003eA chi-square test was conducted to evaluate the association between FVII:C levels (below or above 30%) and the occurrence of bleeding manifestations. The test yielded a Chi-square statistic (χ\u0026sup2;), which is defined as follows: The test yielded a Chi-square statistic (χ\u0026sup2;) of 5.302, with a p-value of 0.0213 and degrees of freedom (dof) of 1. The p-value is less than the conventional threshold of 0.05, indicating a statistically significant association. Pearson's rank correlation test indicated a correlation coefficient of -0.496 (P\u0026thinsp;=\u0026thinsp;0.000) between FVII activity and PT, -0.266 (P\u0026thinsp;=\u0026thinsp;0.014) between FVII activity and haemorrhage score, and 0.149 (P\u0026thinsp;=\u0026thinsp;0.175) between PT and haemorrhage score. The correlations between the first two variables were statistically significant, particularly the relationship between PT and FVII:C, which was highly significant. Conversely, the correlation between PT and haemorrhage score was not statistically significant, suggesting that the observed relationship may have been due to chance.\u003c/p\u003e \u003cp\u003eThe p.Arg364Gln and p.His408Gln variants were the most prevalent, collectively representing 18.37% of the total number of alleles. The Cys10Profs*16 and Arg337Cys variants were also relatively common, collectively accounting for 14.29% of the total number of alleles. The remaining variants exhibited intermediate- and low-frequency distributions(Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eStatistics on the Number of Occurrences and Frequencies of FVII Mutant Alleles in the Study Population\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMutaion\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCount\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eFrequency\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAla251Val\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.010204082\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAla304Thr\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.010204082\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eArg337Cys\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.142857143\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eArg364Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.183673469\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eArg364Trp\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.030612245\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eArg413Pro\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.010204082\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eArg439Ser\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.010204082\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCys10Profs*16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.142857143\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCys389Gly\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.102040816\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGln160Leu\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.010204082\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHis408Gln\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.183673469\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIVS1a\u0026thinsp;+\u0026thinsp;5G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.010204082\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIVS5-1G\u0026thinsp;\u0026gt;\u0026thinsp;A\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.020408163\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIVS6\u0026thinsp;+\u0026thinsp;1G\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.030612245\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIle421Ser*fs76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.010204082\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLeu170*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.010204082\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLys401Glu\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.030612245\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSer329Pro\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.010204082\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eThr241Asn\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.010204082\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTrp344Gly\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.010204082\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eVal384Phe\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.010204082\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ec.805\u0026thinsp;+\u0026thinsp;120C\u0026thinsp;\u0026gt;\u0026thinsp;T\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.010204082\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"4 DISCUSSION","content":"\u003cp\u003eAs of now, the HGMD variant database (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.hgmd.cf.ac.uk/ac/validate.php\u003c/span\u003e\u003cspan address=\"https://www.hgmd.cf.ac.uk/ac/validate.php\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e) has identified 397 variants in the \u003cem\u003eF7\u003c/em\u003e gene, including 261 missense/nonsense variants, which account for 65.7% of the total. Through direct sequencing, we identified pathogenic variants in 39 registered symptomatic cases. However, no variants were identified in 6 symptomatic cases and 20 asymptomatic cases. While direct sequencing offers benefits such as low cost, high accuracy, and a short detection period, it may miss cryptic variants, including heterozygous large deletions or insertions, deep intronic variants, or variants in the promoter region. Furthermore, pathogenic variants were identified in 46 asymptomatic registered cases suggesting that a significant proportion of FVII-deficient patients may remain undetected due to methodological limitations and variability in symptoms. Therefore, the actual number of patients with FVII deficiency disorders may be considerably higher than currently recognized.\u003c/p\u003e \u003cp\u003eIn this study, 25 types of variants were identified in 85 patients with FVII deficiency, with 73.9% occurring in the Peptide S1 region, the main variant-prone area of the \u003cem\u003eF7\u003c/em\u003e gene, and the remaining 26.1% scattered in the Signal peptide, Propeptide, and EGF like-2 regions. The variants included 27 homozygous and 32 compound heterozygous variants, with 14 missense variants accounting for approximately 60.9% of the total, findings that align with the variant database. Approximately 45.45% of the variants were identified in exon 8, indicating that this exon is a major hotspot for variants. This indicates that Exon 8 plays a pivotal role in the gene's functionality, and variants within this region may significantly impact gene functionality. In the context of genetic testing, it is of paramount importance to focus on regions with a high prevalence of variants, with particular emphasis on Exon 8. Prioritising these areas will enhance the accuracy of identifying gene-related variants, thereby improving the sensitivity and specificity of the tests. This approach also provides a robust basis for subsequent functional studies.\u003c/p\u003e \u003cp\u003eFive prevalent variants (p.His408Gln, p.Arg364Gln, p.Cys389Gly, p.Cys10Profs*16, and p.Arg337Cys) were identified in unrelated Chinese families, with the p.His408Gln variant, found in approximately 16% of patients when blood relatives were not present. Current data suggest that p.His408Gln induced low FVII does not prevent the development of VTE[\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e], although clinical manifestations varied considerably among individuals. The p.Arg364Gln variant, located in a CpG dinucleotide hotspot, affects FVII binding to TF, thereby impacting FX activation[\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. The p.Cys389Gly variant disrupts the disulfide bond between p.Cys370 and p.Cys389, affecting protein stability and function, with cases showing a range of presentations from asymptomatic to severe[\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. While primarily associated with non-severe bleeding, rare cases with additional coagulation factor deficiencies (e.g., FX) can lead to lifelong severe bleeding[\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. The p.Cys10Profs16 variant results in a frameshift and premature stop codon, likely resulting in a nonfunctional protein, which may be associated with severe bleeding symptoms. The p.Arg337Cys variant affects the protein's structure and function, and cases with this variant may also exhibit a wide range of clinical manifestations, from mild to severe bleeding.\u003c/p\u003e \u003cp\u003eWe also identified five missense/nonsense variants, including one novel variant and four previously reported by our group. The p.Ser329Pro variant was associated with hemoptysis and resolved with treatment. The p.Gln160Leu variant was linked to recurrent epistaxis, while the p.Leu170* variant was associated with prolonged menstrual symptoms. In both cases, the bleeding symptoms resolved spontaneously without the need for haemostatic treatment. One patient had severe bleeding with a heterozygous p.Trp344Gly variant, while another patient experienced hematuria for over two weeks with a homozygous p.Trp344Gly variant. Further genetic analysis indicated that clinical phenotypes cannot be solely attributed to these variants, suggesting potential interactions with other genetic or environmental factors. ACMG analyses classified these variants as possibly pathogenic or pathogenic.\u003c/p\u003e \u003cp\u003eThe bleeding tendency linked with FVII deficiency can manifest in various ways, ranging from more severe than hemophilia to very mild or even asymptomatic cases. In the study, only 39 out of 85 patients with FVII deficiency experienced bleeding, with excessive menstrual bleeding being the most prevalent symptom among the women. Studies on FVII deficiency have suggested that the reduction in FVII:C may not be associated with bleeding manifestations[\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. However, a statistical analysis of the study cohort yielded markedly different results.\u003c/p\u003e \u003cp\u003eThe chi-square test demonstrated that there is a notable increase in the likelihood of bleeding when FVII:C levels reach a very low point. Pearson's test revealed a statistically significant correlation between FVII:C and both PT and bleeding score. Specifically, there was a statistically significant inverse relationship between PT and FVII:C, with PT demonstrating a decrease as FVII:C increased. Furthermore, a higher FVII:C was associated with a lower bleeding score, although this relationship was weaker and still statistically significant. Conversely, no statistically significant correlation was observed between PT and bleeding score, suggesting that any observed relationship between these two variables may be coincidental. These findings underscore the importance of FVII:C levels in influencing PT and haemorrhage risk, while highlighting the need for further investigation into the factors affecting bleeding scores.\u003c/p\u003e \u003cp\u003eA review of the allele frequencies revealed that the Arg364Gln and His408Gln variants were the most prevalent in the study population. This indicates a significant prevalence of these variants in the study population, which suggests that they may be of high genetic importance or health relevance in this population. Further investigation is required to elucidate the significance of these high-frequency variants. The high frequency of these variants may be associated with specific molecular mechanisms that may have important implications for the pathogenesis of the disease. Future studies should concentrate on investigating the specific functions of these variants in molecular mechanisms, examining their association with related diseases, and exploring their potential for therapeutic applications.\u003c/p\u003e \u003cp\u003eFVII plays a crucial role in the exogenous coagulation pathway, and managing congenital FVII deficiency presents a challenge in accurately assessing bleeding risk. Therefore, FVII preparations are currently the preferred treatment option due to their effectiveness and low risk of blood-borne infections[\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. Recombinant technology offers an effective method for large-scale production of human FVII, accompanied by complex post-translational modifications. Various recombinant expression systems have been established in recent years[\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e], ensuring proper protein folding, accurate post-translational modifications, and correct glycosylation sites. These factors are crucial for maintaining the stability of recombinant proteins, particularly those containing complex disulfide bonds or post-translational modifications. It is hoped that the study of FVII will serve as a reference for the future development in recombinant human FVII using a recombinant expression system[\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e].\u003c/p\u003e"},{"header":"5 CONCLUSION","content":"\u003cp\u003eThis study presents the variant spectrum of FVII deficiency in a southeastern Chinese population, highlighting significant correlations between FVII:C levels and clinical outcomes. The highest allele frequencies were observed in p.Arg364Gln, p.His408Gln, p.Arg337Cys, p.Cys10Profs*16, and p.Cys389Gly, with p.Arg364Gln being the most predominant, suggesting a potential founder effect. The presence of asymptomatic individuals with low FVII:C levels indicates that the prevalence of FVII deficiency may be underestimated. Therefore, comprehensive genetic screening is essential to accurately understand genotype-phenotype correlations. Such screening will improve diagnostic accuracy and inform better management strategies for FVII deficiency in the Chinese population.\u003c/p\u003e"},{"header":"Declarations","content":"\u003ch2\u003eDeclarations\u003c/h2\u003e \u003cp\u003e \u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e \u003cp\u003e The study received approval from the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University (KY2022-R193). All participants provided written informed consent prior to their involvement in the study.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eConsent for publication\u003c/strong\u003e \u003cp\u003eNot applicable.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eCompeting interests\u003c/strong\u003e \u003cp\u003eAll the authors declare no conflicts of interest.\u003c/p\u003e \u003c/p\u003e\u003ch2\u003eFunding\u003c/h2\u003e \u003cp\u003e We would like to acknowledge the support provided by the Wenzhou Basic Medical and Health Science and Technology Project (Y20220125) and the Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province (2022E10022) for this work.\u003c/p\u003e\u003ch2\u003eAuthor Contributions\u003c/h2\u003e \u003cp\u003eLY analyzed data and wrote the manuscript. LQ, SW, YJ, and LY collected the raw data. JP and LY provided advices on interpretation of the results. MW and YX critically reviewed and revised the manuscript. All authors read and approved the final manuscript.\u003c/p\u003e\u003ch2\u003eAcknowledgements\u003c/h2\u003e \u003cp\u003eThe authors express their gratitude to the patients and their family members for their cooperation. They declare no interests that could be perceived as posing a conflict or bias.\u003c/p\u003e\u003ch2\u003eAvailability of data and material\u003c/h2\u003e \u003cp\u003eAll data generated or analyzed during this study are included in this published article. Additional data used in the current study are not publicly available due to privacy restrictions but can be obtained from the corresponding authors upon reasonable request. Please contact Yaosheng Xie (email: [email protected]) or Mingshan Wang (email: [email protected]) for access to the datasets.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eAlexander B, Goldstein R, Landwehr G, Cook CD. Congenital spca deficiency: A hitherto unrecognized coagulation defect with hemorrhage rectified by serum and serum fractions. J Clin Invest. 1951;30(6):596\u0026ndash;608. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1172/jci102477\u003c/span\u003e\u003cspan address=\"10.1172/jci102477\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBernardi F, Mariani G. Biochemical, molecular and clinical aspects of coagulation factor vii and its role in hemostasis and thrombosis. Haematologica. 2021;106(2):351\u0026ndash;62. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3324/haematol.2020.248542\u003c/span\u003e\u003cspan address=\"10.3324/haematol.2020.248542\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLevi M. Disseminated intravascular coagulation in cancer: An update. Semin Thromb Hemost. 2019;45(4):342\u0026ndash;47. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1055/s-0039-1687890\u003c/span\u003e\u003cspan address=\"10.1055/s-0039-1687890\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eElango K, Javaid A, Khetarpal BK, Ramalingam S, Kolandaivel KP, Gunasekaran K, et al. The effects of warfarin and direct oral anticoagulants on systemic vascular calcification: A review. Cells. 2021;10(4). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3390/cells10040773\u003c/span\u003e\u003cspan address=\"10.3390/cells10040773\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCassel A, Rosenberg N, Muhammad E, Livnat T, Dardik R, Berl M, et al. Novel mutation in coagulation factor vii (carmel mutation): Identification and characterization. Res Pract Thromb Haemost. 2021;5(4):e12407. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/rth2.12407\u003c/span\u003e\u003cspan address=\"10.1002/rth2.12407\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePshenichnikova O, Selivanova D, Shchemeleva E, Abramova T, Zozulya N, Surin V. Molecular genetic analysis of russian patients with coagulation factor fvii deficiency. Genes (Basel). 2023;14(9). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3390/genes14091767\u003c/span\u003e\u003cspan address=\"10.3390/genes14091767\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcVey JH, Boswell E, Mumford AD, Kemball-Cook G, Tuddenham EG. Factor vii deficiency and the fvii mutation database. Hum Mutat. 2001;17(1):3\u0026ndash;17. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/1098-1004(2001)17:1\u0026lt;3::Aid-humu2\u0026gt;3.0.Co;2-v\u003c/span\u003e\u003cspan address=\"10.1002/1098-1004(2001)17:1%3C3::Aid-humu2%3E3.0.Co;2-v\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRavanbod S, Faranoush M, Changi-Ashtiani M, Rokni-Zadeh H, Shahani T. Extensive genetic screening of iranian factor fvii-deficient individuals unraveled several novel mutations and postulated founder effects in some cases. Res Pract Thromb Haemost. 2023;7(1):100003. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.rpth.2022.100003\u003c/span\u003e\u003cspan address=\"10.1016/j.rpth.2022.100003\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRichards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the american college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17(5):405\u0026ndash;24. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/gim.2015.30\u003c/span\u003e\u003cspan address=\"10.1038/gim.2015.30\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGiansily-Blaizot M, Rallapalli PM, Perkins SJ, Kemball-Cook G, Hampshire DJ, Gomez K, et al. The eahad blood coagulation factor vii variant database. Hum Mutat. 2020;41(7):1209\u0026ndash;19. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e.https://doi.org/10.1002/humu.24025\u003c/span\u003e\u003cspan address=\".10.1002/humu.24025\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEllingford JM, Ahn JW, Bagnall RD, Baralle D, Barton S, Campbell C, et al. Recommendations for clinical interpretation of variants found in non-coding regions of the genome. Genome Med. 2022;14(1):73. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1186/s13073-022-01073-3\u003c/span\u003e\u003cspan address=\"10.1186/s13073-022-01073-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMohsenian S, Palla R, Menegatti M, Cairo A, Lecchi A, Casini A, et al. Congenital fibrinogen disorders: A retrospective clinical and genetic analysis of the prospective rare bleeding disorders database. Blood Adv. 2024;8(6):1392\u0026ndash;404. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1182/bloodadvances.2023012186\u003c/span\u003e\u003cspan address=\"10.1182/bloodadvances.2023012186\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLuo S, Liu S, Xu M, Li X, Zhang H, Jin Y, et al. Analysis of phenotype and genotype of a family with hereditary coagulation factor v deficiency caused by the compound heterozygous mutations. Blood Coagul Fibrinolysis. 2020;31(7):485\u0026ndash;89. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1097/mbc.0000000000000946\u003c/span\u003e\u003cspan address=\"10.1097/mbc.0000000000000946\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGoodeve AC, Reitsma PH, McVey JH. Nomenclature of genetic variants in hemostasis. J Thromb Haemost. 2011;9(4):852. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e5.https://doi.org/10.1111/j.1538-7836.2011.04191.x\u003c/span\u003e\u003cspan address=\"5.10.1111/j.1538-7836.2011.04191.x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLou C, Jiang J, Chen W, Zhang Z, Xu G, Liu Y, et al. Structural and functional characterization of novel f7 mutations identified in chinese factor vii-deficient patients. Br J Haematol. 2023;202(3):623\u0026ndash;35. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1111/bjh.18768\u003c/span\u003e\u003cspan address=\"10.1111/bjh.18768\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePeters SC, Childers KC, Mitchell CE, Avery NG, Reese SS Jr., Mitchell C, et al. Stable binding to phosphatidylserine-containing membranes requires conserved arginine residues in tandem c domains of blood coagulation factor viii. Front Mol Biosci. 2022;9:1040106. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3389/fmolb.2022.1040106\u003c/span\u003e\u003cspan address=\"10.3389/fmolb.2022.1040106\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAlesci RS, Hecking C, Rack\u0026eacute; B, Janssen D, Dempfle CE. Utility of acmg classification to support interpretation of molecular genetic test results in patients with factor vii deficiency. Front Med (Lausanne). 2023. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10:1220813.https://doi.org/10.3389/fmed.2023.1220813\u003c/span\u003e\u003cspan address=\"10:1220813.10.3389/fmed.2023.1220813\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMenegatti M, Karimi M, Garagiola I, Mannucci P, Peyvandi F. A rare inherited coagulation disorder: Combined homozygous factor vii and factor x deficiency. Am J Hematol. 2004;77(1):90\u0026ndash;1. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/ajh.20132\u003c/span\u003e\u003cspan address=\"10.1002/ajh.20132\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSzczepanik A, Wiszniewski A, Oses-Szczepanik A, Dąbrowski W, Pielaciński K, Misiak A. Surgery in patients with congenital factor vii deficiency - a single center study. Pol Przegl Chir. 2018;90(5):1\u0026ndash;5. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.5604/01.3001.0012.0668\u003c/span\u003e\u003cspan address=\"10.5604/01.3001.0012.0668\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKhan SU, Khan MU, Suleman M, Inam A, Din MAU. Hemophilia healing with aav: Navigating the frontier of gene therapy. Curr Gene Ther. 2024;24(4):265\u0026ndash;77. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.2174/0115665232279893231228065540\u003c/span\u003e\u003cspan address=\"10.2174/0115665232279893231228065540\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWalsh G. Biopharmaceutical benchmarks 2018. Nat Biotechnol. 2018;36(12):1136. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e45.https://doi.org/10.1038/nbt.4305\u003c/span\u003e\u003cspan address=\"45.10.1038/nbt.4305\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"},{"header":"Unsectioned Paragraphs","content":"\u003cp\u003e\u003cb\u003eRunning title: Spectrum of Variants in the\u003c/b\u003e \u003cb\u003eF7\u003c/b\u003e \u003cb\u003eGene\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eAbbreviations\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eFVII\u003c/b\u003e Coagulation factor VII\u003c/p\u003e\u003cp\u003e\u003cb\u003eFVII:C\u003c/b\u003e Coagulation factor VII activity\u003c/p\u003e\u003cp\u003e\u003cb\u003eICH\u003c/b\u003e Including intracranial hemorrhage\u003c/p\u003e\u003cp\u003e\u003cb\u003eELISA\u003c/b\u003e Enzyme-linked immunosorbent assay\u003c/p\u003e\u003cp\u003e\u003cb\u003ePCR\u003c/b\u003e Polymerase chain reaction\u003c/p\u003e\u003cp\u003e\u003cb\u003ePT\u003c/b\u003e Prothrombin time\u003c/p\u003e\u003cp\u003e\u003cb\u003eAPTT\u003c/b\u003e Activated partial thromboplastin time\u003c/p\u003e\u003cp\u003e\u003cb\u003eFⅡ:C\u003c/b\u003e Coagulation factor Ⅱ activity\u003c/p\u003e\u003cp\u003e\u003cb\u003eFⅤ:C\u003c/b\u003e Coagulation factor Ⅴ activity\u003c/p\u003e\u003cp\u003e\u003cb\u003eFⅩ:C\u003c/b\u003e Coagulation factor Ⅹ activity\u003c/p\u003e\u003cp\u003e\u003cb\u003eLA\u003c/b\u003e Lupus anticoagulant\u003c/p\u003e\u003cp\u003e\u003cb\u003eGB\u003c/b\u003e Gingival bleeding\u003c/p\u003e\u003cp\u003e\u003cb\u003eEP\u003c/b\u003e Epistaxis\u003c/p\u003e\u003cp\u003e\u003cb\u003eSB\u003c/b\u003e Subcutaneous bleeding\u003c/p\u003e\u003cp\u003e\u003cb\u003eMN\u003c/b\u003e Menorrhagia\u003c/p\u003e\u003cp\u003e\u003cb\u003ePB\u003c/b\u003e Postoperative bleeding\u003c/p\u003e\u003cp\u003e\u003cb\u003ePPH\u003c/b\u003e Postpartum Hemorrhage\u003c/p\u003e\u003cp\u003e\u003cb\u003eGI-MA\u003c/b\u003e Gastrointestinal Melena\u003c/p\u003e\u003cp\u003e\u003cb\u003eEB\u003c/b\u003e Easy to bruise\u003c/p\u003e\u003cp\u003e\u003cb\u003eHU\u003c/b\u003e Hematuria\u003c/p\u003e\u003cp\u003e\u003cb\u003eSDH\u003c/b\u003e Subdural haematoma\u003c/p\u003e\u003cp\u003e\u003cb\u003eN\u003c/b\u003e No bleeding\u003c/p\u003e\u003cp\u003e\u003cb\u003eF\u003c/b\u003e Female\u003c/p\u003e\u003cp\u003e\u003cb\u003eM\u003c/b\u003e Man\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Factor VII Deficiency, Inherited bleeding disorders, Variant, Gene frequence","lastPublishedDoi":"10.21203/rs.3.rs-4674402/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4674402/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eFactor VII (FVII) deficiency is a rare congenital coagulation disorder inherited in an autosomal recessive manner, characterized by reduced plasma FVII levels. Several variants in the F7 gene have been identified across different populations, with higher prevalence in certain regions. However, limited reports exist on predominant variants in Chinese and East Asian populations, highlighting the need for this study to fill the gap and improve understanding of genotype-phenotype correlations.\u003c/p\u003e\u003ch2\u003eResult\u003c/h2\u003e \u003cp\u003eThis study characterizes severe FVII deficiency in 85 unrelated Chinese families, 57 exhibited severe FVII defects. Notably, 31 out of 57 experienced various bleeding manifestations, with the most prevalent being gingival bleeding, epistaxis, and menorrhagia. The Pearson's rank correlation test yielded correlation coefficients of \u0026minus;\u0026thinsp;.496 (P\u0026thinsp;=\u0026thinsp;.000), \u0026minus;\u0026thinsp;.266 (P\u0026thinsp;=\u0026thinsp;.014), and .149 (P\u0026thinsp;=\u0026thinsp;.175) between FVII activity and PT, FVII activity and bleeding scores, and PT and bleeding scores, respectively. Direct sequencing of the exons of the \u003cem\u003eF7\u003c/em\u003e gene and its border regions was conducted on all patients. The five variants with the highest allele frequencies were p.Arg364Gln, p.His408Gln, p.Arg337Cys, p.Cys10Profs16, and p.Cys389Gly. The p.Arg364Gln variant was identified in 11 individuals with homozygotes and 6 with compound heterozygosity, with the highest allele frequency of 30.51%. The variants p.Gln160Leu, p.Leu170*, p.Ser329Pro, and p.Trp344Gly were previously identified and reported by our research group. Additionally, a novel variant, p.Ile421Serfs76, is reported for the first time. This study, representing one of the largest cohorts of FVII variants in China, suggests that the prevalence of FVII deficiency may be underestimated. This conclusion is supported by the high proportion of asymptomatic subjects found to have low FVII levels.\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eThe findings of this study, which represents one of the largest cohorts of FVII variants in China, indicate that the prevalence of FVII deficiencies may be underestimated. This is due to the high proportion of asymptomatic individuals with low FVII:C levels. The significant association between FVII:C levels, prothrombin time, and bleeding symptoms highlights the necessity for continued genetic analysis to enhance our comprehension of genotype-phenotype correlations and to refine diagnostic and management strategies for FVII deficiency in the Chinese population.\u003c/p\u003e","manuscriptTitle":"Recurrent Founder Variant in Inherited FVII Deficiency: Molecular Spectrum Analysis in Southeast China Recurrent Founder Variant in Inherited FVII Deficiency: Molecular Spectrum Analysis in Southeast China","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-09-04 21:56:38","doi":"10.21203/rs.3.rs-4674402/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"5808ba4f-5448-4de1-9922-3f5c06f5d050","owner":[],"postedDate":"September 4th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2024-10-07T05:13:26+00:00","versionOfRecord":[],"versionCreatedAt":"2024-09-04 21:56:38","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4674402","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4674402","identity":"rs-4674402","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}